Nanogen Pharmaceutical Biotechnology JSC
↗Ho Chi Minh City, Vietnam
Nanogen Pharmaceutical Biotechnology is a research-driven biotechnology company based in Vietnam, specializing in the development and manufacturing of active pharmaceutical ingredients (APIs) and finished therapeutic products. The company utilizes advanced recombinant DNA and protein technologies to produce a wide range of biopharmaceuticals, including biosimilars, monoclonal antibodies, and cytokines, with a focus on oncology, immunology, and infectious diseases.
Established in 1997, Nanogen operates state-of-the-art manufacturing facilities compliant with WHO-GMP and TGA-GMP standards. The company is recognized as a leader in the Asia-Pacific region for its integrated 'lab-to-market' capabilities, which include R&D, clinical trial management, and large-scale production of high-quality, affordable biotherapeutic products for both domestic and international markets.
CLASSIFICATION
Company Type:Biotech
Therapeutic Areas:
Industry:Biotechnology
Sub-Industry:Biosimilars and Biopharmaceuticals
SIZE & FINANCIALS
Founded:1997
Ownership:private
Status:operating
PIPELINE
Stage:Commercial
Lead Drug Stage:Commercial
Modalities:Recombinant proteins, Monoclonal antibodies, Biosimilars
Active Trials:11
Trial Phases:-
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Key Partnerships:Sartorius (Process development and purification technology collaboration)
COMPETITION
Position:Emerging
Competitors:Biocad, Celltrion, Biocon
LEADERSHIP
Key Executives:
Nhan Ho - CEO
LINKS
Website:nanogenpharma.com
⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Nanogen Pharmaceutical Biotechnology JSC and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Nanogen Pharmaceutical Biotechnology JSC. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.